Calif. biotech gets $13.5M funding boost

05/7/2013 | American City Business Journals

NGM Biopharmaceuticals secured almost $13.5 million in an equity offering targeted at $50 million, a securities filing showed. Rather than betting on a single drug, NGM is using a basic-science approach to uncover how genes, hormones and receptors regulate diabetes, obesity and other cardiometabolic disorders. The company hopes to develop a treatment that mimics the benefits of gastric bypass surgery, which has been shown to improve type 2 diabetes outcomes even before weight loss begins.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX